Theragenics Reports Revenue And Earnings For The Second Quarter And First Half Of 2012

Theragenics Corporation ® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended June 30, 2012.

Highlights
  • Consolidated revenue
    • $22.0 million for the second quarter of 2012, up 2% over 2011
    • $43.5 million for the first half of 2012, up 4% over 2011
  • Segment revenue
    • Surgical products revenue up 3% in second quarter over 2011 and up 5% for the first half of 2012
    • Brachytherapy revenue up 1% in second quarter over 2011 and up 3% for the first half of 2012
  • Incremental revenue in Brachytherapy segment from acquired Core customers was $1.2 million in the second quarter of 2012 and $1.8 million for the first half of 2012
  • Earnings per share
    • $0.02 in the second quarter of 2012 compared to $0.04 in 2011
    • $0.05 for the first half of 2012 compared to $0.05 in 2011
  • Adjusted EBITDA
    • $3.7 million in the second quarter of 2012 compared to $4.0 million in 2011
    • $7.5 million for the first half of 2012 compared to $6.8 million in 2011
  • Pursuant to our modified Dutch Auction tender offer, we repurchased 4,761,904 common shares on July 17, 2012 for an aggregate purchase price of $10.0 million. Total cost including transaction costs was approximately $10.4 million.
  • Cash flow
    • At June 30, 2012, cash, cash equivalents and marketable securities were $38.7 million and credit facility borrowings were $22.0 million, resulting in a net positive position of $16.7 million.
      • Cash flow from operations was $4.9 million for the first half of 2012, compared to $3.4 million in 2011.
      • $4.8 million in cash was used in the first half of 2012 for the Core transaction, which closed in February 2012.
        • Another $4.6 million is expected to be paid through September 2013 for remaining payments on this earn-out based asset acquisition.
      • Capital expenditures were $982,000 in the first half of 2012.
      • $1.7 million of principal payments were made on the term loan in the first half of 2012. At June 30, 2012 the term loan was completely paid in full. Our $30 million line of credit facility matures on October 31, 2012.
    • On a pro forma basis, assuming our Dutch Auction share repurchase was completed on June 30, 2012, our net positive position was $6.3 million.

Segment Results

Surgical Products Segment

Revenue in our surgical products segment was $15.9 million in the second quarter of 2012, an increase of 3% over the second quarter of 2011 and our highest quarterly revenue ever in our surgical products segment. For the first half of 2012 revenue was $31.4 million, an increase of 5% over 2011. Operating income for the quarter was $588,000 compared to $498,000 in 2011. For the first half of 2012 operating income was $787,000 compared to $307,000 in 2011. Pre-tax charges for special items totaling $35,000 and $218,000 were included in the second quarter and first half, respectively, of 2011. The pre-tax charges for special items are detailed in Table V to this press release. No such special items were incurred in the 2012 periods.

If you liked this article you might like

Theragenics Corporation Stock Downgraded (TGX)

Theragenics' CEO Discusses Q2 2012 Results - Earnings Call Transcript

7 Stocks Under $10 Soaring Higher

Theragenics Corporation CEO Discusses Q1 2012 Results - Earnings Call Transcript

Theragenics Corporation Stock Upgraded (TGX)